1.1
Tafamidis is not recommended, within its marketing authorisation, for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.
Closed for comments This consultation ended on at Request commenting lead permission
Tafamidis is not recommended, within its marketing authorisation, for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.
This recommendation is not intended to affect treatment with tafamidis that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Why the committee made these recommendations
ATTR-CM is a progressive condition that can lead to heart failure. Current treatment options are limited to managing symptoms and best supportive care. Tafamidis is the first treatment for ATTR-CM that aims to treat the condition.
Evidence from the main clinical trial shows that tafamidis reduces deaths and hospitalisations from conditions affecting the heart and blood vessels compared with placebo. There is longer-term follow-up evidence from this trial on how long people live when taking tafamidis and how long they take tafamidis for.
There are uncertainties in the economic model for tafamidis, including how long the effect of treatment lasts after it is stopped. The most likely cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources. So, tafamidis is not recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Document
Question on Document
Question on Document
Question on Document